Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Goemaere

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Plos One|February 19, 2013
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South AfricaMiguel Angel Luque-Fernandez, Gilles Van Cutsem, Eric Goemaere, et al.
Tropical Medicine & International Health : TM & IH|June 4, 2014
Community-supported models of care for people on HIV treatment in sub-Saharan AfricaMarielle Bemelmans, Saar Baert, Eric Goemaere, et al.
Lancet (London, England)|May 20, 2014
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialMolebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, et al.
International Journal of Epidemiology|May 22, 2016
Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South AfricaKathryn Stinson, Eric Goemaere, David Coetzee, et al.
AIDS (London, England)|January 9, 2010
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South AfricaAndrew Boulle, Gilles Van Cutsem, Katherine Hilderbrand, et al.
Wellcome Open Research|August 26, 2022
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialYing Zhao, Claire Keene, Rulan Griesel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2023
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeksClaire M Keene, Tali Cassidy, Ying Zhao, et al.
Plos Medicine|December 7, 2007
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemicDavid Heiden, Nathan Ford, David Wilson, et al.
Science (New York, N.Y.)|July 17, 2012
Public health. Getting HIV treatment to the most peopleSharonann Lynch, Nathan Ford, Gilles van Cutsem, et al.
AIDS (London, England)|May 11, 2021
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimenClaire M Keene, Rulan Griesel, Ying Zhao, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Plos One|February 19, 2013
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South AfricaMiguel Angel Luque-Fernandez, Gilles Van Cutsem, Eric Goemaere, et al.
Tropical Medicine & International Health : TM & IH|June 4, 2014
Community-supported models of care for people on HIV treatment in sub-Saharan AfricaMarielle Bemelmans, Saar Baert, Eric Goemaere, et al.
Lancet (London, England)|May 20, 2014
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialMolebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, et al.
International Journal of Epidemiology|May 22, 2016
Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South AfricaKathryn Stinson, Eric Goemaere, David Coetzee, et al.
AIDS (London, England)|January 9, 2010
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South AfricaAndrew Boulle, Gilles Van Cutsem, Katherine Hilderbrand, et al.
Wellcome Open Research|August 26, 2022
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialYing Zhao, Claire Keene, Rulan Griesel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2023
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeksClaire M Keene, Tali Cassidy, Ying Zhao, et al.
Plos Medicine|December 7, 2007
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemicDavid Heiden, Nathan Ford, David Wilson, et al.
Science (New York, N.Y.)|July 17, 2012
Public health. Getting HIV treatment to the most peopleSharonann Lynch, Nathan Ford, Gilles van Cutsem, et al.
AIDS (London, England)|May 11, 2021
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimenClaire M Keene, Rulan Griesel, Ying Zhao, et al.
Pageof 6